Investigation of revers-transcriptase polymerase chain reaction values of patients with COVID-19 findings in lung computed tomography results
It turned out that the cause of pneumonia cases that occurred in China was due to SARS-CoV-2. The aim is to compare chest computer tomography and Revers-Transcriptase Polymerase Chain Reaction methods used in the diagnosis of COVID-19 disease with each other and to evaluate this disease with risk factors.
The study was carried out on 66 patients. Epidemiological history, clinical symptoms, chest CT and RT-PCR results of the cases were examined. RT-PCR results of 1, 4, and 7 days were evaluated for each case with positive chest CT results. Thirty-seven of them were found to be positive on day 1, 5 of them were found to be positive on day 4, and 2 of them were found to be positive on day seven from 52 patients whose RT-PCR results were examined. In the remaining 8 cases, no positive findings were found. The most common findings are; cough (78.8%), fever (55.8%), and shortness of breath (28.8%). It was observed that 51.9% of the cases had chronic disease history and 50% of the patients using cigarettes had bilateral lung involvement in their CT results. Seven cases received intensive care support, 3 cases were intubated. Two of the intubated cases were exitus (3,8%). The positive results of RT-PCR were found to be negative in most of the cases which have positive chest CT; suggests that chest CT is more reliable in making a diagnosis. Therefore, evaluating chest CT results with RT-PCR can be an appropriate alternative approach in the diagnosis and treatment of disease. However, in order to be fully diagnosed, the patient's history, chronic diseases, age, symptoms, imaging, blood, and test findings must all be considered as a whole.
There is no Figure or data content available for this article
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Feb 28 2020. DOI: 10.1056/NEJMoa2002032
3. Ebrahim S, Ahmed QA, Gozzer E, Schlagenhauf P, Memish ZA. Covid-19 and community mitigation strategies in a pandemic. BJM. 2020;368:1-2. https://doi.org/10.1136/bmj.m1066
4. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome. Journal of Autoimmunity. 2020;10(2):2-5. https://doi.org/10.1016/j.jaut.2020.102452
5. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. Jan 23 2020. https://doi.org/10.1001/jama.2020.0757
6. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. Mar 2020;579(7798):265-269. https://doi.org/10.1038/s41586-020-2008-3
7. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. Feb 15 2020;201(4):P7-P8. https://doi.org/10.1164/rccm.2014p7
8. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. Mar 4 2020. https://doi.org/10.1007/s11606-020-05762-w
9. Luo S, Zhang X, Xu H. Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). Clin Gastroenterol Hepatol. Mar 20 2020. https://doi.org/10.1016/j.cgh.2020.03.043
10. Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19). Am J Otolaryngol. Apr 4 2020:102474. https://doi.org/10.1016/j.amjoto.2020.102474
11. Guo D, Xia J, Shen Y, Tong J. SARSâ€CoVâ€2 may be related to conjunctivitis but not necessarily spread through the conjunctiva SARSâ€CoVâ€2 and conjunctiva. Medical Virology. 2020;4(1):15-19. https://doi.org/10.1002/jmv.25856
12. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. Treasure Island (FL); 2020. https://www.ncbi.nlm.nih.gov/books/NBK554776/
13. Erol A. High-dose intravenous vitamin C treatment for COVID-19. Accessed Mar 12, 2020. https://doi.org/10.31219/osf.io/p7ex8
14. Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19. Infections and Deaths Nutrients. 2020;12(4):988. https://doi.org/10.3390/nu12061620
15. Yang, S., Zhang, M., Yin, L., Wang, K., Zhou, Y., Zhou, M., & Lu, Y. COVID-19 Treatment: Close to a Cure?â€“A Rapid Review of Pharmacotherapies for the Novel Coronavirus. Preprints. 2020. doi: 10.20944/preprints202003.0378.v1
16. Shetty AK. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19). Induced Pneumonia Aging and disease. 2020;11(2):462. https://doi.org/10.14336/ad.2020.0301
17. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. Mar 26 2020;368:m1198. https://doi.org/10.1136/bmj.m1198
18. Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking. Nicotine. Tobacco Research. 2020;4(1):5-7. https://doi.org/10.1093/ntr/ntaa059
19. Ramesh N, Siddaiah A, Joseph B. Tackling coronavirus disease 2019 (COVID 19) in workplaces. Indian Journal of Occupational and Environmental Medicine. 2020;24(1):16. https://doi.org/10.4103/ijoem.ijoem_49_20
20. Shirbandi K, Barghandan S, Mobinfar O, Rahim F. Inactivation of Coronavirus with Ultraviolet Irradiation: What? How? Why? SSRN. 2020. https://doi.org/10.2139/ssrn.3571418
21. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. Feb 19 2020:200432. https://doi.org/10.1148/radiol.2020200432
22. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. Feb 15 2020;395(10223):514-523. https://doi.org/10.1016/s0140-6736(20)30154-9
23. Zhonghua Liu Xing Bing Xue Za Zhi. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Feb 17 2020;41(2):145-151. https://doi.org/10.46234/ccdcw2020.032
24. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Mar 28 2020;395(10229):1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3
25. Yen N, Lee E, Yang J, et al. Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. Radiology: Cardiothoracic Imaging. 2020;2(1):11-15. https://doi.org/10.1148/ryct.2020200034
26. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. Lancet Respir Med. Feb 24 2020. https://doi.org/10.1016/s2213-2600(20)30079-5
27. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. Feb 21 2020. doi:10.1001/jama.2020.2565
28. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. Mar 12 2020. https://doi.org/10.1093/cid/ciaa248
29. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;2(3):10-12. https://doi.org/10.1007/s00134-020-06028-z
30. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. Apr 10 2020. https://doi.org/10.1016/j.jinf.2020.03.041
31. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. Feb 19 2020. https://doi.org/10.1111/all.14238
32. Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review. Int J Environ Res Public Health. May 21 2018;15(5). https://doi.org/10.3390/ijerph15051033
33. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. Nov 8 2004;164(20):2206-2216. https://doi.org/10.1001/archinte.164.20.2206
34. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20. https://doi.org/10.18332/tid/119324
35. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. Feb 26 2020:200642. https://doi.org/10.1148/radiol.2020200642
36. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ. Mar 25 2020;368:m1182. https://doi.org/10.1136/bmj.m1182
37. de La Vega MA, Bello A, Chaillet P, Kobinger GP. Diagnosis and management of Ebola samples in the laboratory. Expert Rev Anti Infect Ther. Jun 2016;14(6):557-567. https://doi.org/10.1080/14787210.2016.1176912
How to Cite This
Copyright and Permissions
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.